Clinical Trials Browser

Phase 1/2 × abemaciclib × 1 year × Clear all

NCT06498648 2026-03-18

Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma

Phase 1/2 Recruiting

Leiomyosarcoma, Liposarcoma, Sarcoma

NCT03424005 2026-03-16

Morpheus-panBC

Phase 1/2 Recruiting

Breast Neoplasms

NCT04802759 2026-03-16

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer

Phase 1/2 Recruiting

Neoplasm Metastasis

NCT07100106 2026-03-12

A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer

Phase 1/2 Recruiting

Breast Neoplasms

NCT04238819 2026-03-02

A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma

Phase 1/2 Completed

47 enrolled 36 charts

Diffuse Intrinsic Pontine Glioma, Brain Neoplasms, Ependymoma, Glioblastoma, Glioma, Medulloblastoma, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma, Rhabdoid Tumor

NCT06188520 2026-02-24

CYCAD-1

Phase 1/2 Recruiting

BreastGynecologic

ER+ HER2- Advanced Breast Cancer

NCT05548127 2026-02-10

TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A)

Phase 1/2 Active not recruiting

Breast Neoplasms

NCT04923542 2026-02-06

Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases

Phase 1/2 Recruiting

Brain Neoplasms

NCT05386108 2026-02-05

ELECTRA

Phase 1/2 Recruiting

Brain Diseases, Brain Neoplasms, Breast Diseases, Breast Neoplasms, Central Nervous System Diseases, Neoplasms, Neoplasms by Site, Central Nervous System Neoplasms

NCT06810544 2026-02-02

Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss

Phase 1/2 Recruiting

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Glioma, Lung Neoplasms

NCT04941274 2026-01-23

Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma

Phase 1/2 Recruiting

Acquired Immunodeficiency Syndrome, Sarcoma, Kaposi

NCT06835972 2026-01-15

A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC)

Phase 1/2 Recruiting

Carcinoma, Renal Cell

NCT07002177 2026-01-07

A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC

Phase 1/2 Recruiting

Breast Neoplasms

NCT04616183 2025-12-23

LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer

Phase 1/2 Active not recruiting

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT03284957 2025-11-24

AMEERA-1

Phase 1/2 Terminated

136 enrolled 60 charts

Breast Neoplasms

NCT05867251 2025-11-19

Study of AVZO-021 in Patients With Advanced Solid Tumors

Phase 1/2 Recruiting

BreastGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Fallopian Tube Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT03280563 2025-11-10

MORPHEUS HR+BC

Phase 1/2 Completed

144 enrolled 25 charts

Breast Neoplasms

NCT05608252 2025-10-29

VS-6766+Abema+Fulv in Met HR+/HER- BC

Phase 1/2 Recruiting

Breast Neoplasms

NCT05735080 2025-09-19

INX-315-01

Phase 1/2 Recruiting

BreastGynecologic

Breast Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms

NCT05113537 2025-09-18

UPLIFT

Phase 1/2 Recruiting

Prostatic Neoplasms

NCT04486352 2025-09-04

EndoMAP

Phase 1/2 Recruiting

Endometrial Neoplasms

NCT05095207 2025-04-02

Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer

Phase 1/2 Recruiting

Breast Neoplasms, Neoplasm Metastasis

NCT06594679 2025-03-28

NICHOL

Phase 1/2 Recruiting

Ovarian Neoplasms